The Claim
Among patients who have experienced a myocardial infarction, initiating ezetimibe therapy within 12 weeks is associated with a reduced risk of cardiovascular death over a 3-year period compared to delayed initiation or no use, with a hazard ratio of 1.83 (95% CI: 1.35–2.69) for those not using ezetimibe versus early users.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you've had a heart attack, starting a cholesterol drug called ezetimibe within 3 months might lower your chance of dying from heart problems over the next 3 years, compared to waiting or not taking it at all.
See the scientific wording
Among patients after myocardial infarction, early initiation of ezetimibe (within 12 weeks) is associated with a lower risk of cardiovascular death over 3 years compared to delayed initiation or no use, with a hazard ratio of 1.83 (95% CI: 1.35–2.69) for no ezetimibe versus early use.
What the research says
1 studyThe study found that patients who started ezetimibe soon after a heart attack were less likely to die from heart problems over 3 years compared to those who didn’t, and the numbers match exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.